Enteromedics Inc (ETRM) 0.20 $ETRM EnteroMedics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enteromedics Inc (ETRM) 0.20 $ETRM

EnteroMedics Announces First-of-its-Kind Procedure with vBloc® Therapy Used as Adjunctive Rescue Treatment for Failed Gastric Sleeve in Patients with Obesity
PR Newswire - Wed Jun 01, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced a first-of-its-kind procedure in which the Company's vBloc® Neurometabolic Therapy was used as an adjunctive rescue treatment in two patients with obesity who failed to achieve sufficient weight loss and diabetes control with their previous gastric sleeve surgeries.
ETRM: 0.20 (unch)

EnteroMedics to Host vBloc® Commercialization Update Conference Call
PR Newswire - Mon May 23, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, as previously guided, it will host a conference call to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy on Wednesday, June 1, 2016 at 11:00 AM Eastern Time. The call will be led by Dan W. Gladney, the Company's President and Chief Executive Officer.
ETRM: 0.20 (unch)

EnteroMedics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:19PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2016.
ETRM: 0.20 (unch)

EnteroMedics Announces Closing of $6.25 Million Third Tranche of Previously-Announced Convertible Notes Offering
PR Newswire - Tue May 03, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the third tranche of the $25 million Senior Amortizing Convertible Notes (the "Notes" offering announced on November 5, 2015, has closed, for proceeds of $6.25 million. Prior to this most recent closing, EnteroMedics received $12.5 million in proceeds under the agreement. The original securities purchase agreement, which consisted of three tranches, has been amended to allow for a fourth tranche of $6.25 Million. This final tranche must be drawn or waived on or prior to August 15, 2016. The Company intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes.
ETRM: 0.20 (unch)

EnteroMedics Announces Exclusive Federal Government Business Channel Sales Agreement with Academy Medical to Provide vBloc® Neurometabolic Therapy to US Department of Veterans Affairs Medical Facilities
PR Newswire - Mon May 02, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its vBloc® Neurometabolic Therapy to U.S. Department of Veterans Affairs (VA) medical facilities. Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and Department of Defense (DoD) hospitals and community-based outpatient clinics.
ETRM: 0.20 (unch)

Weight Loss Surgery Foundation of America to Include EnteroMedics vBloc® Therapy as Part of the Grant Referral Program
PR Newswire - Thu Apr 21, 6:00AM CDT
Weight Loss Surgery Foundation of America and EnteroMedics Inc. (NASDAQ: ETRM) announced today that Weight Loss Surgery Foundation of America will include EnteroMedics vBloc® Therapy in their grant referral program starting June 1, 2016.
ETRM: 0.20 (unch)

EnteroMedics Announces Publication of Results Showing Significantly Greater Weight Loss in vBloc® Patients with Moderate Obesity
PR Newswire - Tue Apr 05, 1:44PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of results from the Company's ReCharge Study on the effect of vBloc® Neurometabolic Therapy in patients with moderate obesity with an obesity-related comorbid condition. In this population, patients saw 74% greater weight loss with vBloc therapy compared to a rigorous sham control, resulting in an average loss of 33% of excess weight at 12 months. Further, three quarters of patients lost at least 20% of their excess weight and a quarter lost at least 50%. The publication, entitled "Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: The ReCharge Study," was published in the journal Obesity Surgery and is available online here.
ETRM: 0.20 (unch)

EnteroMedics to Present at the 28th Annual ROTH Conference
PR Newswire - Wed Mar 09, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Dan Gladney, Chief Executive Officer, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 11:00 AM Pacific Time at the Ritz Carlton in Dana Point, CA.
ETRM: 0.20 (unch)

EnteroMedics to Host Fourth Quarter 2015 Financial Results and Commercialization Update Conference Call
PR Newswire - Wed Feb 03, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, February 17, 2016 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2015 and to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy.
ETRM: 0.20 (unch)

Winthrop-University Hospital Becomes First Employer in the U.S. to Cover Innovative Obesity Treatment vBloc Therapy
PR Newswire - Tue Feb 02, 4:44PM CST
Winthrop-University Hospital and EnteroMedics Inc. announced today that Winthrop-University Hospital has become the first employer in the United States to add vBloc Neurometabolic Therapy as an included benefit for its nearly 8,000 eligible employees and their spouses. As a leader in the field of bariatric surgery, Winthrop-University Hospital recently made headlines as an innovator with vBloc Therapy, as one of the first sites in the country to offer this treatment for obesity to its patients. Winthrop-University Hospital is a vBloc Institute and part of EnteroMedics' IDN Partnership program.
ETRM: 0.20 (unch)

EnteroMedics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Jan 22, 4:22PM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, in accordance with NASDAQ Listing Rule 5635(c)(4), its Board of Directors has approved inducement awards as a component of employment compensation for three recently appointed executives: Paul Hickey, Senior Vice President of Marketing and Reimbursement, Nick Ansari, Senior Vice President of Sales, and Peter DeLange, Senior Vice President of Operations and Business Development.
ETRM: 0.20 (unch)

EnteroMedics Announces Closing of $11 Million Tranche from Previously-Announced Convertible Notes Offering
PR Newswire - Wed Jan 13, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the second tranche of the $25 million Senior Amortizing Convertible Notes (the "Notes" offering announced on November 5, 2015, has closed, for proceeds of $11 million. EnteroMedics received $1.5 million at the initial closing on November 9, 2015. The third and final tranche, for proceeds of $12.5 million, is scheduled to fund in approximately 45 days. The Company intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes.
ETRM: 0.20 (unch)

EnteroMedics Announces Senior Level Appointments, New Commercial Operations Organization Structure
PR Newswire - Wed Jan 06, 3:53PM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced senior level appointments within its newly reorganized commercial operations group. The appointments include Paul Hickey as Senior Vice President of Marketing and Reimbursement, Nick Ansari as Senior Vice President of Sales, and Peter Delange as Senior Vice President of Operations and Business Development. With the addition of these new roles, EnteroMedics is shifting its commercial organization toward several, highly focused commercial areas headed by executives with significant leadership experience.
ETRM: 0.20 (unch)

EnteroMedics Announces Publication in SOARD of ASMBS Position Statement on Vagal Blocking Therapy for Obesity
PR Newswire - Tue Jan 05, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of a position statement on vagal blocking therapy for obesity by Pavlos Papasavas, MD, Maher El Chaar, MD and Shanu N. Kothari, MD, on behalf of the American Society for Metabolic and Bariatric Surgery (ASMBS), in the journal Surgery for Obesity and Related Diseases. The position statement was prepared after review by the ASMBS Clinical Issues Committee and is available online here.
ETRM: 0.20 (unch)

STERIS (STE) Hits 52-Week High on Robust FY16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 12:35PM CST
STERIS' shares closed at $76.95 yesterday, translating into a decent one-year return of around 18.1%.
ETRM: 0.20 (unch), MASI: 52.74 (-0.19), STE: 70.91 (-0.50), EXAC: 26.97 (-0.23)

STERIS Up on Robust FY16 Outlook; Segments Reorganized
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 1:30PM CST
The Synergy health acquisition has enabled STERIS (STE) to expand its already robust presence in North America to the developed markets of Europe as well as the emerging markets of Asia-Pacific and Latin America.
ABMD: 117.93 (-1.57), ETRM: 0.20 (unch), MASI: 52.74 (-0.19), STE: 70.91 (-0.50)

EnteroMedics Announces 1-for-15 Reverse Split
PR Newswire - Wed Dec 23, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced shareholder approval for three proposals: (1) an amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to effect a reverse split of its issued and outstanding shares of common stock; (2) an increase in the number of shares of common stock authorized for issuance effective after the reverse stock split; and (3) the issuance of shares of the Company's common stock underlying convertible notes and warrants issued by EnteroMedics pursuant to the terms of a securities purchase agreement dated November 4, 2015.
ETRM: 0.20 (unch)

EnteroMedics to Host Year-end Company Update Conference Call
PR Newswire - Tue Dec 08, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, as previously guided, it will host a year-end conference call on Thursday, December 17, 2015 at 11:00 AM Eastern Time to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy, delivered via the Maestro® System, as well as other recent Company developments. The call will be led by Dan W. Gladney, the Company's recently appointed President and Chief Executive Officer.
ETRM: 0.20 (unch)

Mindray Medical and Masimo Agree to Settle All Disputes
Zacks Equity Research - Zacks Investment Research - Tue Nov 24, 3:40PM CST
Mindray Medical International Limited (MR) and Masimo Corporation (MASI) recently agreed to settle all disputes in the U.S. and China.
BABY: 38.74 (-0.44), ETRM: 0.20 (unch), MASI: 52.74 (-0.19), MR: 27.94 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 28

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 161

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 342

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 24

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Mercy Medical Center Nurses Mobilize for Patient Safety Picket

Updated Category News Views 35

Nurses Standing Together for Patient Safety Nurses at Mercy Medical Center are uniting for a cause that affects them profoundly: the safety of their patients and the workplace. With issues surrounding unsafe staffing and deteriorating care conditions, nurses represented by the Massachusetts Nurses Association plan to hold an informational picket. This demonstration is not...

Continue Reading
Massive Merger: Qorvo and Skyworks Unite for Future Innovations

Updated Category News Views 306

Overview of the Strategic Merger In an exciting development in the technology sector, shares of Qorvo, Inc. (NASDAQ: QRVO) and Skyworks Solutions, Inc. (NASDAQ: SWKS) are experiencing a notable surge after announcing their intent to merge. This deal, which values the combined entity at approximately $22 billion, marks a significant step forward in the realm of...

Continue Reading
Oryzon Genomics Announces Corporate Updates for September

Updated Category News Views 178

Oryzon Genomics to Share Updates on Corporate Progress Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a leading clinical-stage biopharmaceutical company dedicated to epigenetic therapies for critical medical needs, is set to present its latest corporate updates at several major international events. These important gatherings scheduled for September will showcase...

Continue Reading
Envision Energy Launches Innovative Energy Storage Solution

Updated Category News Views 363

Introducing the EN 8 Pro: A Revolution in Energy Storage Envision Energy, a leader in sustainable technology, has made a significant breakthrough in energy management with the launch of its EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System. This innovative setup is set to establish new industry standards in safety, efficiency, and environmental adaptability. Designed...

Continue Reading
Beard Papa's Teams Up for Exciting Zenless Zone Zero Launch

Updated Category News Views 528

Beard Papa's Exciting Flavor Collaboration Begins Beard Papa's, renowned for its delectable cream puffs and irresistible custard fillings, is thrilled to announce a nationwide collaboration with Zenless Zone Zero. This partnership will launch an exciting in-game event that will allow fans to experience the unique flavors inspired by the action-RPG sensation from...

Continue Reading